
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio is on track for the development nominee of their AATD program in the second quarter of 2026, with their current lead program, KRRO-121, being focused on treating hyperammonemia in urea cycle disorders and hepatic encephalopathy. The company has shown promising data for their subcutaneous RNA editing technology, with single-dose in vivo data showing high potency and repeat dosing achieving over 90% editing and protein correction. With a clear value proposition and a substantial market opportunity for their potential treatments, the company's stock has the potential for significant growth in the future.
Bears say
Korro Bio is a biopharmaceutical company with a unique approach to genetic medicines. Despite the promising science and potential for high peak sales, there are fundamental concerns about execution and regulatory expectations for their lead candidate KRRO-121 in hyperammonemia, with potential for limited efficacy and safety issues. The company's current valuation does not reflect these risks, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares